Sabrina Martucci Johnson is the Founder and CEO of Daré Bioscience (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Prior to founding Daré, Sabrina was President of WomanCare Global Trading, a global provider of women’s health products, CFO/CAO of the California Institute for Biomedical Research (currently Calibr-Skaggs Institute for Innovative Medicines, part of Scripps Research), CFO/COO of Cypress Bioscience, Inc. (NASDAQ:CYPB), held marketing positions with Advanced Tissue Sciences, and began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on the recombinant factor VIII program. Sabrina has a Master of International Management with honors from the American Graduate School of International Management (Thunderbird); a MSc. in Biochemical Engineering from the University of London, University College London; and a BSc. in Biomedical Engineering from Tulane University, magna cum laude. Sabrina currently serves on the boards of ATAI Life Sciences, a publicly-traded biopharmaceutical company aiming to transform the treatment of mental health disorders, BIOCOM California board chair, and BIO board member. She was recognized as one of Fierce Pharma’s Most Influential People in Biopharma for contributions to innovation and advocacy in the women’s health space.